[go: up one dir, main page]

AR094018A1 - Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos - Google Patents

Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos

Info

Publication number
AR094018A1
AR094018A1 ARP130104746A ARP130104746A AR094018A1 AR 094018 A1 AR094018 A1 AR 094018A1 AR P130104746 A ARP130104746 A AR P130104746A AR P130104746 A ARP130104746 A AR P130104746A AR 094018 A1 AR094018 A1 AR 094018A1
Authority
AR
Argentina
Prior art keywords
arrhythmias
prevention
treatment
funny current
caninos
Prior art date
Application number
ARP130104746A
Other languages
English (en)
Inventor
Lang Ingo
Christian Meil Joerg
Seidler Randolph
Markert Michael
Kley Saskia
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR094018A1 publication Critical patent/AR094018A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un bloqueante lᶠ, o una de sus sales farmacéuticamente aceptables para el tratamiento y/o prevención de un paciente canino que sufre de enfermedades cardíacas, con preferencia enfermedades cardíacas tales como cardiomiopatía dilatada (DCM), insuficiencia de la válvula mitral (MI), arritmias, con preferencia taquiarritmias, arritmias con preferencia arritmias atriales, arritmias atrioventriculares nodales y/o taquicardia. Reivindicación 14: El inhibidor de corriente funny (lᶠ) o una de sus sales farmacéuticamente aceptables para usar en un método de acuerdo con cualquiera de las reivindicaciones 12 a 13, caracterizado porque el inhibidor de corriente funny (Iᶠ) se selecciona del grupo que consiste en cilobradina, zatebradina, ivabradina y anilidina, con preferencia es cilobradina.
ARP130104746A 2012-12-14 2013-12-13 Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos AR094018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12197371 2012-12-14

Publications (1)

Publication Number Publication Date
AR094018A1 true AR094018A1 (es) 2015-07-01

Family

ID=47358383

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104746A AR094018A1 (es) 2012-12-14 2013-12-13 Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos

Country Status (5)

Country Link
US (1) US20140171415A1 (es)
EP (1) EP2931262A1 (es)
AR (1) AR094018A1 (es)
TW (1) TW201436795A (es)
WO (1) WO2014090842A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741735A1 (en) 2011-08-12 2014-06-18 Boehringer Ingelheim Vetmedica GmbH Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
ES2851923T3 (es) * 2016-05-20 2021-09-09 Nestle Sa Triglicéridos de cadena intermedia para el tratamiento de enfermedad degenerativa de la válvula mitral en animales de compañía
ES2963110T3 (es) * 2018-12-27 2024-03-25 Nestle Sa Composiciones y métodos para el diagnóstico y tratamiento de la enfermedad degenerativa de la válvula mitral en caninos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
WO2014090842A1 (en) 2014-06-19
TW201436795A (zh) 2014-10-01
EP2931262A1 (en) 2015-10-21
US20140171415A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
CL2017001871A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
IL234181B (en) Method for mapping ventricular/atrial premature beats during sinus rhythm
CY1118839T1 (el) Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη
EP2498797A4 (en) TREATMENT OF CARDIOPATHY
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
PE20141452A1 (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmaceuticas que las usan
MX362098B (es) El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica.
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
UY36416A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de la mieloperoxidasa
AR094018A1 (es) Inhibidores de corrientes funny (if) para utilizar en un metodo de tratamiento y/o prevencion de la enfermedad cardiaca en caninos
CY1118294T1 (el) Εστερες καρβοξυλικου οξεος αμιδοξιμης της δαβιγατρανης ως προφαρμακα και η χρηση αυτων ως φαρμακο
EA201291431A1 (ru) Состав для укладки волос
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
AR105752A1 (es) Métodos para el tratamiento de enfermedades cardiovasculares
WO2015074010A3 (en) Compositions and methods for cardiac regeneration
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
MX2018004380A (es) Compuestos de aminotiolesteres o sus sales farmaceuticamente aceptables para usarse en el tratamiento del cancer.
CY1118645T1 (el) Χρηση pidotimod στη θεραπεια της ψωριασης
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure